MNKD MANNKIND CORP

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business: biopharmaceutical company focused on inhalation drug delivery and proprietary pulmonary technologies
• • New emphasis: multiple amendments (up to seventh) to Commercial Supply Agreement with United Therapeutics Corporation in current year

Risk Factors

• • Regulatory risk: Inflation Reduction Act of 2022 limited insulin copays to $35/month for Medicare Part D starting 2023, pressuring Afrezza pricing and reimbursement
• • Geopolitical risk: V-Go wholly manufactured in China, exposed to U.S.-China trade tensions and potential tariff changes affecting margins

Management Discussion & Analysis

• • No revenue or profitability data provided in the overview section
• • Cardiometabolic segment consists of Afrezza, Furoscix, V-Go device with recent acquisition of scPharma in Oct 2025

Management Discussion & Analysis

• • Revenue $82.1M for Q3 FY25, up 17% YoY from $70.1M; Nine months revenue $237.0M, up 14% YoY from $208.7M
• • Commercial product gross margin 80% Q3 FY25 vs 84% in Q3 FY24; Nine months margin 80% vs 79% YoY

Risk Factors

• • New risk: Acquisition-related integration risk triggered by October 2025 scPharma purchase, including increased interest expense and potential net debt impact
• • Updated operational risk: Manufacturing complications and supply chain challenges intensified by tariffs and U.S.-China trade tensions affecting V-Go production

What are the latest MNKD SEC filings in 2026?

MANNKIND CORP (MNKD) has filed a 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 5, 2025, an 8-K current report on February 26, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did MNKD file its most recent 10-K annual report?

MANNKIND CORP (MNKD) filed its most recent 10-K annual report on February 26, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view MNKD 10-Q quarterly reports?

MANNKIND CORP (MNKD)'s most recent 10-Q quarterly report was filed on November 5, 2025. SignalX displays every MNKD 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has MNKD filed recently?

MANNKIND CORP (MNKD)'s most recent 8-K was filed on February 26, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find MNKD insider trading activity (Form 4)?

SignalX aggregates every MNKD Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does MNKD file with the SEC?

MANNKIND CORP (MNKD) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new MNKD filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for MANNKIND CORP (MNKD).

What is MNKD's SEC CIK number?

MANNKIND CORP (MNKD)'s SEC CIK (Central Index Key) number is 899460. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 899460 to look up all MNKD filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find MNKD return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from MANNKIND CORP (MNKD) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.